-transparent.png){kind=logo}
Two recombinant interferons-alpha (IFNs-alpha) were assayed for their antiviral effect on hepatitis A virus (HAV) replication in the human hepatoma cell line PLC/PRF/5. IFN alpha-2a and IFN alpha-2b resulted in concentration-dependent inhibition of HAV antigen expression and HAV infectivity at non toxic concentrations. Their selectivity indices, calculated as the ratio of the dose that reduced the number of viable cells to 50% (CD50) to the effective dose that inhibited 50% of viral antigen expression (ED50) were > 1000. Recombinant IFN-alpha emerged, from the present study, as a promising candidate for chemotherapy of hepatitis A.
Related Publications
J M Crance, and
R Deloince, and
F Leveque, and
A Jouan, and
C Trépo
March 1998,
Arzneimittel-Forschung,
J M Crance, and
R Deloince, and
F Leveque, and
A Jouan, and
C Trépo
December 1985,
Journal of virology,
J M Crance, and
R Deloince, and
F Leveque, and
A Jouan, and
C Trépo
June 1990,
Revista medica de Chile,
J M Crance, and
R Deloince, and
F Leveque, and
A Jouan, and
C Trépo
January 2012,
Voprosy virusologii,
J M Crance, and
R Deloince, and
F Leveque, and
A Jouan, and
C Trépo
November 1999,
Journal of hepatology,
J M Crance, and
R Deloince, and
F Leveque, and
A Jouan, and
C Trépo
June 2007,
Virus research,
J M Crance, and
R Deloince, and
F Leveque, and
A Jouan, and
C Trépo
February 1992,
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
J M Crance, and
R Deloince, and
F Leveque, and
A Jouan, and
C Trépo
October 1989,
American journal of veterinary research,
J M Crance, and
R Deloince, and
F Leveque, and
A Jouan, and
C Trépo
November 1992,
The Journal of infectious diseases,
J M Crance, and
R Deloince, and
F Leveque, and
A Jouan, and
C Trépo
February 2003,
Journal of medical virology,
